|
26.08.25 - 18:48
|
Multiconsult ASA – Status on share buy-back (Cision)
|
|
Multiconsult ASA (OSE: MULTI) announced on 24 February 2025 a non-discretionary agreement with DNB Markets, a part of DNB Bank ASA for the repurchase of up to 500 000 of its ordinary shares in the market with the purpose to meet obligations arising from Multiconsult's employee share saving programme and executive management bonus schemes. As part of this, a portion of the purchased shares has been used to settle the loan under the share loan agreement with its largest shareholder Stiftelsen Multiconsult.
From 18 August - 26 August 2025, Multiconsult ASA has purchased a total of 36 651 own...
|
|
26.08.25 - 11:01
|
Zalaris announces Gold Partnership at HR Connect Melbourne 2025 (Cision)
|
|
Zalaris, a leading provider of HR and payroll solutions and services, is excited to announce its participation in HR Connect Melbourne 2025 as a Gold Partner.
The event will take place on Tuesday, 9 September 2025, at The Glasshouse, Olympic Park Oval, Olympic Blvd, Melbourne VIC, bringing together HR and business leaders from across Australia and beyond to explore the future of human experience management.
HR Connect Melbourne (https://events.sap.com/au-hr-connect-melbourne/en_us/home.html) provides a dynamic platform for HR professionals to gain insights into cutting-edge SAP solutions,...
|
|
22.08.25 - 10:01
|
Zalaris ASA: Invitation to Q2 2025 webcast (Cision)
|
|
Zalaris ASA will release its second quarter 2025 results on Friday 29 August at 07:00 CET.
Zalaris will host a webcast for all shareholders and interested parties on 29 August at 08:30 CET. There will be a Q&A session following the management presentation.
The webcast will be available on zalaris.com (https://zalaris.com/about/investors) or directly on Teams (https://teams.microsoft.com/l/meetup-join/19%3ameeting_MTVmMzZlM2QtMDZlYy00ZjQyLTk0Y2UtYzJhNTcyZTY1ZTI4%40thread.v2/0?context=%7B%22Tid%22%3A%22a16eb8e2-803d-4f22-849c-f3f335a60a39%22%2C%22Oid%22%3A%22bf49dddc-8238-4b99-a279-...
|
|
20.08.25 - 16:36
|
Atea ASA - share buyback (Cision)
|
|
Oslo, 20 August 2025
Please see below information about transactions made under the share buyback program for Atea ASA.
Date on which the buyback program was announced: 18 August 2025.
The duration of the buyback program: 18 August 2025 to 30 April 2026, or until the maximum number of shares has been repurchased.
Size of the buyback program: Up to 800,000 shares
From 18 August 2025 until 20 August 2025, Atea ASA has purchased a total of 30,000 own shares at the Oslo Stock Exchange at an average price of NOK 144.56 per share.
Following the completion of the above...
|
|
20.08.25 - 09:42
|
Atea Share Savings Program – notification of trade (Cision)
|
|
Reference is made to the stock exchange notice on August 9, 2023, regarding the Employee Share Savings Program.
Under the terms of the Program, participating employees may allocate a fixed amount of their monthly after-tax salary to purchase shares in Atea ASA (up to a maximum per month of NOK 1,000 in Norway, SEK 1,000 in Sweden, DKK 700 in Denmark and EUR 100 per month in Finland and the Baltic countries). Shares are purchased by employees from Atea ASA's treasury share holdings at market price. The price of the shares purchased is determined based on the volume-weighted average price...
|
|
19.08.25 - 08:30
|
Nordhealth AS: Q2/2025 results presentation and H1 2025 interim financial report (Cision)
|
|
Please find attached the presentation of Nordhealth AS Q2/2025 results, and the interim financial report of Nordhealth AS for H1/2025.
The results will be presented in a live webcast and subsequent Q&A session with CEO Charles MacBain and CFO Alexander Cram on the 19th of August 2025 at 16:30 CEST.
Please use the following link to attend: https://us02web.zoom.us/j/86765127004
The presentation will be recorded and made available on www.nordhealth.com
For further information, please contact:
Charles MacBain, CEO
charles.macbain@nordhealth.com
+44 75 3903 2200
Alexander...
|
|
|
18.08.25 - 08:06
|
Initiation of share repurchase program (Cision)
|
|
The Board of Directors of Atea ASA has resolved to initiate a share repurchase program. The share repurchase program is in accordance with the power of attorney granted to the Board by the Annual General Meeting of Atea ASA on April 29, 2025.
The share repurchase program will be for a maximum consideration of NOK 140 million, and for a maximum of 800,000 shares. The program will commence on August 18, 2025 and continue until April 30, 2026 or until the maximum number of shares has been repurchased. Buyback transactions will be executed according to the market price on the Oslo Stock...
|
|
18.08.25 - 07:42
|
Multiconsult ASA – Status on share buy-back (Cision)
|
|
Multiconsult ASA (OSE: MULTI) announced on 24 February 2025 a non-discretionary agreement with DNB Markets, a part of DNB Bank ASA for the repurchase of up to 500 000 of its ordinary shares in the market with the purpose to meet obligations arising from Multiconsult's employee share saving programme and executive management bonus schemes. As part of this, a portion of the purchased shares has been used to settle the loan under the share loan agreement with its largest shareholder Stiftelsen Multiconsult.
From 7 August - 15 August 2025, Multiconsult ASA has purchased a total of 19 974 own...
|
|
14.08.25 - 06:01
|
Webstep ASA: Second quarter results 2025 (Cision)
|
|
Oslo, 14 August 2025: Webstep ASA today reports revenues of NOK 215.0 million for the second quarter 2025, a decline of 6.3 per cent from NOK 229.5 million in the same period last year. The EBIT margin was 8.9 per cent, up from 8.3 per cent, with EBIT stable at NOK 19.0 million.
While average hourly rates were higher than in the second quarter 2024, reflecting Webstep's ambition to maintain premium positioning in the market despite price pressures, the revenue decline was primarily a result of a decline in utilisation and a slight reduction in the number of consultants.
In recent quarters,...
|
|
13.08.25 - 16:06
|
Nordhealth AS - Invitation to Q2 2025 presentation (Cision)
|
|
Nordhealth will report and present its Q2 2025 results on Tuesday the 19[th] of August 2025.
The results will be presented in a live presentation and subsequent Q&A session with CEO Charles MacBain and CFO Alexander Cram on the 19[th] of August at 16:30 CEST.
Please use the following link to attend: https://us02web.zoom.us/j/86765127004
The presentation will be recorded and made available on www.nordhealth.com. The presentation material for Q2/2025 will be available on 19[th] August 2025 at 08:30 CEST on www.newsweb.no (https://publish.ne.cision.com/l/afkpudtpe/www.newsweb.no) and...
|
|
12.08.25 - 12:30
|
Invitation to presentation of second quarter and half year result 2025 (Cision)
|
|
Multiconsult (OSE: MULTI) second quarter and half year results 2025 will be released on Tuesday 19 August at 07:00 CET. Multiconsult hereby invites you to the presentation of the results and participants are invited to attend.
The Norwegian presentation will be held at Hotel Continental, Stortingsgata 24/26, Oslo, at 08:15. The presentations will be held by Grethe Bergly (CEO) and Ove B. Haupberg (CFO).
The results will also be presented through live webcasts: In Norwegian at 08:15 and in English at 09:30. Participants will have the opportunity to submit questions online throughout the...
|
|
08.08.25 - 09:06
|
#teamZalaris finishes the Zalaris Norseman Xtreme Triathlon, raising a legendary NOK 5 million to combat cancer (Cision)
|
|
For the sixth consecutive year, Zalaris proudly served as the title sponsor of the Zalaris Norseman Xtreme Triathlon - a race that many claim is the world's toughest triathlon, a race so demanding it's said to “make triathletes cry.” This extraordinary event is designed to celebrate the resilience and determination of ordinary people doing the extraordinary.
The 2025 #teamZalaris featured a strong lineup of athletes including CEO and founder of Zalaris Hans-Petter Mellerud (Norway) along with Carolina Laurentiu (Spain), Anders Rasmussen (Denmark), Ross Creber (UK), Gro Hege Viberg Jermstad (...
|
|
|
|
07.08.25 - 11:24
|
Webstep ASA: Announcement of financial results Q2 2025 (Cision)
|
|
Oslo, 7 August 2025: Please note that Webstep ASA will announce its second quarter 2025 results 14 August 2025.
The interim report, presentation and webcast will be available from 7:00 am CET at:
https://investor.webstep.com/Investors/reports-and-presentations/default.aspx...
|
|
06.08.25 - 18:06
|
Multiconsult ASA – Status on share buy-back (Cision)
|
|
Multiconsult ASA (OSE: MULTI) announced on 24 February 2025 a non-discretionary agreement with DNB Markets, a part of DNB Bank ASA for the repurchase of up to 500 000 of its ordinary shares in the market with the purpose to meet obligations arising from Multiconsult's employee share saving programme and executive management bonus schemes. As part of this, a portion of the purchased shares has been used to settle the loan under the share loan agreement with its largest shareholder Stiftelsen Multiconsult.
From 29 July - 6 August 2025, Multiconsult ASA has purchased a total of 21 444 own...
|
|
|
04.08.25 - 09:07
|
Zalaris shortlisted for 4 payroll awards from the Chartered Institute of Payroll Professionals (Cision)
|
|
Zalaris is proud to announce that it has once again been shortlisted for multiple accolades by the Chartered Institute of Payroll Professionals (CIPP), reinforcing its continued excellence in payroll, HR, and outsourcing services.
The CIPP Annual Excellence Awards (https://www.cipp.org.uk/events/annual-excellence-awards.html) are among the most prestigious in the payroll industry, celebrating outstanding achievements and contributions to the profession.
This year, Zalaris has been nominated in the following categories:
· Software Innovation Product of the Year
· Software of the...
|
|
31.07.25 - 13:03
|
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025 (GlobeNewswire EN)
|
|
BOSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, August 7, 2025, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2025, and to provide a business update....
|
|